Welcome to our dedicated page for Cardio Diagnostics Holdings SEC filings (Ticker: CDIOW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Cardio Diagnostics Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Cardio Diagnostics Holdings's regulatory disclosures and financial reporting.
Cardio Diagnostics Holdings, Inc. director Peter K. Fung received a grant of stock options for 3,205 shares of Common Stock at an exercise price of $1.95 per share on March 31, 2026. Following the grant, he holds stock options for a total of 9,513 shares, expiring on March 31, 2036.
Cardio Diagnostics Holdings, Inc. director Wendy J. Betts received a grant of stock options covering 3,205 shares of Common Stock. The options have an exercise price of $1.95 per share and expire on March 31, 2036. Following this award, she directly holds 9,513 stock options.
Intrater James reported acquisition or exercise transactions in this Form 4 filing.
Cardio Diagnostics Holdings director James Intrater received a grant of 3,205 stock options on Common Stock at $1.95 per share. These options were granted on March 31, 2026 and expire on March 31, 2036. Following the award, he holds 10,464 stock options directly.
Cardio Diagnostics Holdings director Burton Paul Frederick received a grant of stock options as compensation. He was awarded 3,205 options to buy Common Stock at an exercise price of $1.95 per share, expiring on March 31, 2036. Following this grant, he holds 10,464 derivative securities directly.
Cardio Diagnostics Holdings is hosting an investor call to review its current status, recent developments, and strategic priorities, supported by an investor presentation. The company focuses on precision cardiovascular medicine using epigenetics and artificial intelligence to prevent and detect heart disease earlier and more accurately.
The presentation highlights two AI-powered blood tests: Epi+Gen CHD, which estimates three-year coronary heart disease risk and has an estimated U.S. market of about $125 billion with 146 million eligible Americans, and PrecisionCHD, a diagnostic aid with an estimated $51 billion U.S. market and 60 million eligible Americans, both tied to a final CMS payment rate of $854 per test. Management emphasizes growing clinical validation, cost-effectiveness studies, and international partnerships, including a recently launched internal CLIA lab that has reduced initial lab cost of goods by roughly 30% and targets test turnaround times of about 7–10 business days.